Appendix from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Year: 2023
Type: other
Abstract: Supplementary Table 1: 3 + 3 dose escalation guidelines Supplementary Table 2: Customized sequencing panel Supplementary Table 3: Summary of AEs occurring in >20% of all patients, treatment-related AEs and SAEs Supplementary Table 4: PK parameters following single dose oral dosing of GSK2636771 (PK population) Supplementary Table 5: PK parameters following single daily oral dosing of GSK2636771 (PK population) Supplementary Table 6: PK parameters following multiple dose oral dosing of GSK2636771 (PK population)
Authors: Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung-Jue Bang, Jeffrey R. Infante, Li Yan, Johann S. de Bono, Hendrik-Tobias Arkenau
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361931799